The critical importance of basic animal research for neuropsychiatric disorders

Neuropsychopharmacology

Volumn 44, Issue 8, 2019, Pages 1349-1353

  Bale, Tracy L ^a   Abel, Ted ^b   Akil, Huda ^c   Carlezon, William A ^d   Moghaddam, Bita ^e   Nestler, Eric J ^f   Ressler, Kerry J ^d   Thompson, Scott M ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF IOWA   (United States)

^c UNIVERSITY OF MICHIGAN   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

^e OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^f MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT;

ANIMAL BEHAVIOR; ARTICLE; BASIC RESEARCH; BRAIN FUNCTION; CELL DEATH; CELL INTERACTION; CHRONIC STRESS; COPING BEHAVIOR; DEPRESSION; DRUG INDUSTRY; ELECTROPHYSIOLOGY; EPIGENETICS; GENE SEQUENCE; GENETIC RISK; GENOME-WIDE ASSOCIATION STUDY; HEALTH PROGRAM; HUMAN; INDUCED PLURIPOTENT STEM CELL; MEDICAL RESEARCH; MENTAL DISEASE; MOLECULAR PATHOLOGY; MOOD DISORDER; NEUROSCIENCE; NONHUMAN; OUTCOME ASSESSMENT; PHENOTYPE; POSTTRAUMATIC STRESS DISORDER; PRIORITY JOURNAL; RISK FACTOR; SIGNAL TRANSDUCTION; SOCIAL BEHAVIOR; ANIMAL; DISEASE MODEL; DRUG DEVELOPMENT; PROCEDURES;

ANIMALS; DISEASE MODELS, ANIMAL; DRUG DISCOVERY; HUMANS; MENTAL DISORDERS;

EID: 85065501355     PISSN: 0893133X     EISSN: 1740634X     Source Type: Journal    
DOI: 10.1038/s41386-019-0405-9     Document Type: Article

References (10)

1. Quadrato G, Brown J, Arlotta P. The promises and challenges of human brain organoids as models of neuropsychiatric disease. Nat Med. 2016;22:1220–8.
2. Nestler EJ, Hyman SE. Animal models of neuropsychiatric disorders. Nat Neurosci. 2010;13:1161–9.
3. Selye H. Stress and disease. Science. 1955;122:625–31.
4. Nemeroff CB, Vale WW. The neurobiology of depression: inroads to treatment and new drug discovery. J Clin Psychiatry. 2005;66:5–13.
5. Akil H, Gordon J, Hen R, Javitch J, Mayberg H, McEwen B, et al. Treatment resistant depression: a multi-scale, systems biology approach. Neurosci Biobehav Rev. 2018;84:272–88.
6. LeDoux JE, Pine DS. Using neuroscience to help understand fear and anxiety: a two-system framework. Am J Psychiatry. 2016;173:1083–93.
7. Conn PJ, Roth BL. Opportunities and challenges of psychiatric drug discovery: roles for scientists in academic, industry, and government settings. Neuropsychopharmacol. 2008;33:2048–60.
8. Willner P. The chronic mild stress (CMS) model of depression: history, evaluation and usage. Neurobiol Stress. 2016;6:78–93.
9. Drysdale AT, Grosenick L, Downar J, Dunlop K, Mansouri F, Meng Y, et al. Resting-state connectivity biomarkers define neurophysiological subtypes of depression. Nat Med. 2017;23:28–38.
10. Trullas R, Skolnick P. Functional antagonists at the NMDA receptor complex exhibit antidepressant actions. Eur J Pharmacol. 1990;185:1–10.